Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Recruiting · NCT05419726 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of California, Los Angeles
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.
Who can take part
Inclusion criteria
- Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
- \>18 years of age and willing to participate
- Male or post-menopausal females
Exclusion criteria
- History of prior neck surgery and /or neck irradiation
- Use of beta blocker agents
- Use of any other glucose lowering medication
- History of neuropathic disorders (e.g. diabetic neuropathy)
- Diabetic patients
- Individuals without normal thyroid function
- Individuals with cancer
- Any significant chronic disease or renal, hepatic or endocrine disease
- Current smokers
- Inability of patient to provide consent either for medical reasons or psychiatric reasons
Where it is running
1 location listed across 1 US state.
- UCLA Health - Los Angeles, California, United States